Zadzwoń do nas: 16 677 00 79, 16 671 87 77

ul. św Jana 32, Przemyśl Mapa

Paź 29

COVID-19 can be treated in 48 hours

COVID-19 can be treated in 48 hours

Dear readers.

My name is Włodzimierz Bodnar. I am a paediatrician and also a specialist in lung diseases, who has been treating patients continuously for over 30 years. I am writing as a practitioner, but also a person from the risk group (age and profession) that is himself a post-covid patient. With your help, I would like to implement/publish a treatment on how to overcome a severe case of disease caused by SARS-CoV-2. This is my appeal to the people of science and medicine of the world.


Being unheard

Let me explain first why I decided to publish this article. In the period between March and October 2020, I have documented over 100 COVID-19 cured cases – most of them quite acute – and more than a dozen more come every day. Some of these patients had comorbidities that increase the risk of serious health hazard and death.

Currently, I am convalescing myself after surviving a severe COVID-19 attack (confirmed by RT-PCR test). I am 59 years old and belong to a high-risk group for cardiac reasons. By using the method described below, my symptoms began to retreat 48 hours after starting treatment.

Now, I feel well enough, wholly cured and able to write this message myself, as well as treat patients continuously over the phone and in my clinic, in person. Each of my patients going through an acute phase of the infection keeps in touch and informs me about their health daily for the period of 3-4 days. 

In the last couple of months, most of my attempts at communicating this successful and innovative method of treatment failed. The institutions I have contacted included:

  • March 2020 Polish Ministry of Health – no answer
  • March 2020 Professor Katherine Kędzierski, chairman of Australian scientists (The Peter Doherty Institute for Infection and Immunity) – no answer
  • April 2020 Professor Krzysztof Simon, Department of Infectious Diseases Wrocław – no answer
  • In the meantime, multiple repeated attempts to reach the government and its representatives were unsuccessful
  • In July 2020, I published a description of my cases of treating patients which was sent to doctors all over Poland (Porozumienie Zielonogórskie) – unfortunately without much response
  • Also in July 2020, I received the only ever answer – a positive response came from Szczecin from Professor Cezary Pakulski, Department of Intensive Care Anaesthesiology and Emergency Medicine, who fully supported my observations. It restored my faith and strength to continue healing and writing about it
  • October 2020, Before getting sick, I published an article about how to treat COVID-19 in the local press – no significant response, even before my disease and recent treatment adjustments
  • I have been sending this message everywhere possible for the past ten days, without any answer received from neither the government nor the media

I strongly believe that with this method of treatment, at least 90% of severe, currently hospitalized, cases in Poland (or even worldwide) can be stabilized within 48 hours followed by a recovery period of several more days. 

Thanks to its wide availability and the usage of a well-tested drug, it will stop the disease before it does significant damage. It would also considerably change the way we are fighting the pandemic right now. Having an effective, safe drug changes everything.

The hypothesis

If we assume that we are looking for an antiviral drug that works directly against the virus, then, in this case, amantadine is entirely useless. If we believe that amantadine or some other medication will significantly alter the conditions of viral growth, an investigation is further needed. Viruses must have a well-defined host in which they ‘multiply’. I want to emphasize that a virus can only grow under the right conditions.

There has been research on how amantide works in general, and also how it can potentially work in case of SARS-CoV-2 infection (1). Still, for a practitioner, the most important thing is having a drug that changes the conditions of a virus’s development in a human cell and makes it unable to spread. This way, we can save health and life if the patient is still alive. 

After reaching the appropriate concentration of the drug – we act on the virus, deactivating it at every stage of the disease. In other words, in each case, we work on the cause of the disease, i.e. the virus, by eliminating it from the body (deactivation), be it the initial period of headaches or the late stage of pneumonia. It does not matter whether the patient is 30 or 100 years old, has comorbidities or not. The principle of the approach is the same, and it is to deactivate the virus. 

Deduction process and recommended scheme

To be more specific, my experiences and further research have focused only on Amantadine hydrochloride (Amantadini hydrochloridum), which – for reading purposes – I keep naming “amantadine”, which may or may not be an essential aspect of the treatment. Further research is required. 

Focusing on practice now: my observations from the 30-year period of treating viral diseases were helpful and, unfortunately, the last 60 days of the dynamically growing number of COVID-19 cases in Poland ‘helped me’ even more to gather data. 

I have come across a lot of very acute cases started by SARS-CoV-2. COVID-19 infections are much more severe than influenza that is easier to treat. Why? Because the dynamics of the latter disease is much slower. For example, if we look at the patient’s weight loss, COVID-19 patients lose about one kilogram of weight a day (most often lying in bed, doing nothing and drinking even more fluids than usual). From the perspective of a practitioning doctor, this proves that the disease is very dynamic. 

Initial treatment attempts, as in the case of influenza, may be insufficient because the symptoms of COVID-19 last much longer, i.e. 4 to 9 days. 

Singular studies about the potential positive influence of amantadine on COVID-19 have been conducted, but without any spectacular results (2). The reason here may be an insufficient dose of the drug fortherapeutic purposes. I started treatment with a different dose of amantadine. In this way, in most cases, there was a dramatic improvement after one day. Stabilization took place after two days, without major disease symptoms except for the sometimes slightly tiring cough. Thus, I came to premature conclusions that complete virus inactivation takes place in 72 hours, which does not have to be true. I emphasize that this is only my assumption, science will speak for itself in the future.

However, knowing the dynamics of the virus, it is safer to maintain prophylactic treatment until the body is sufficiently immune if there was a relapse of the disease. In a small percentage, amantadine can cause early arrhythmogenic symptoms. In the event of the occurrence of side effects, discontinue treatment completely no matter the stage of treatment. That is why constant everyday contact with a doctor is a key during this treatment.

When the disease is enormously progressing

When the patient’s medical history shows that the progress of the disease is very dynamic and acute (symptoms begin to increase hour by hour), we may suspect that in extreme cases the patient may be at risk of dying within a few hours. Seeing the effects of the therapy, I decided to race against time and introduce one more change to the treatment to shorten the time to reach the saturated therapeutic level as much as possible. 

In this model, I already have a lot of feedback where patients literally ‘get on their feet’ in a short time.

Why rapid treatment is important and additional recommendations

With quick treatment, we can avoid disability or irreversible changes in the body, complications or long-term treatment of other diseases e.g. pneumonia.

In addition to taking amantadine, the recommendation is a symptomatic treatment for e.g. fever. As in any disease, it is up to the doctor to decide on the antibiotic, if the virus has damaged internal organs, or during the regeneration and treatment of the consequences of COVID-19. Time is of the essence because the virus causes great damage to the body. Please keep in mind that the recovery process can depend on how late treatment with this regimen is started.

Here, I would also like to comment that postmortem publications describing clotting syndromes in patients may not be valid. These changes can be caused by a very severe cough, where the blood vessels in the chest burst. The patient’s breathing reflex is turned off, and they experience difficulty speaking (speech is effort), pain is stronger than breathing reflex.

The summary

The main drug (active substance) AMANTADINE, I am considering, is not included in the COVID-19 treatment regimens for now, although it is a drug known for about 30-40 years and used to treat other diseases. It is well-tested, known worldwide. With the use of it, we are already talking about causal treatment – that is, complete inactivation of the virus. It no longer works on the body, which is why the effect is so much improved. 

Once a virus has been deactivated, it will never attempt to replicate again. It takes at least 24 hours for the drug to enter the body in sufficient quantity and to change the environment for the virus. 

I expect that this drug will be immediately implemented in COVID-19 treatment scheme and may revolutionize the fight with pandemic worldwide, saving the health and life of millions.

Why am I doing this?

Seeing the effects both on the patients, who physically visit my clinic in a dozen or so a day, and telephone cases from all over Poland asking for help in saving lives, I cannot be indifferent to the situation. Only in the Podkarpackie Province, the number of positive results of SARS-CoV-2 tests ranges from 30% to even 93% (3), which may indicate a much broader scale of infections than we assume.

Knowing about the adequate daily dosage (48-72hours) and feedback on the effects, I decided in the favour of this publication to clearly show that I was able to stabilize over 90% of severe cases within 48 hours. Later, it is ‘just’ the treatment necessary after the damage already made by the virus. 

I do not plan to shy away from responsibility. This article is signed with my name, mentioning my specialization, and making me available for contact from both doctors and the media.

I live in suspense with the full awareness that people are dying. From my perspective, I have the feeling that the vast majority of them can potentially be cured, but there is nothing more I can do. Attempts at a scientific approach or media contact have not been successful for months. Therefore, I decided to act differently and present my conclusions in the form of an appeal of a practitioner to the general public with a request to spread this information as a bottom-up initiative.

After a few days, we have more and more publicity, also among doctors, but there is still dead silence in the main media channels. I know it has to change sometime soon. I want to thank all the people for their active participation in my appeal.

Włodzimierz Bodnar, 

Specialist in lung diseases, Paediatrician at NZOZ Optima in Przemyśl, Poland

The author declares no conflict of interest.

For media and medical inquiries, please contact us at:

This email is not for patients; we will not reply to any of those requests.

Note: Treatment should be carried out only on the recommendation of a doctor (the drug is on prescription), and the treatment itself is combined with symptomatic treatment and diet restrictions. CANNOT BE USED BY A PATIENT WITHOUT CONSTANT CONTACT WITH A DOCTOR!


  1. Amantadine as a drug to mitigate the effects of COVID-19
  2. Amantadine Treatment for People with COVID-19
  3. SARS-CoV-2 results in the Podkarpackie Province:

Additional note: If you intend to publish this article on other sites, please always include the link to the original to ensure continuity for future updates.

In Polish + comments section (also treated patients stories):

Image: CDC/ Alissa Eckert, MS; Dan Higgins, MAM –

Włodzimierz Bodnar
Specialist in lung diseases, Paediatrician at NZOZ Optima in Przemyśl, Poland

Polish version with comments section:

Komentarze (136)

Dodaj komentarz
  1. 23 lutego 2021, 19:25 Odpowiedz
  2. 21 lutego 2021, 18:04
    Coinfection with influenza A virus enhances SARS-CoV-2 infectivity Odpowiedz
  3. 19 lutego 2021, 20:10 Odpowiedz
  4. 7 lutego 2021, 20:49
    A B C D Odpowiedz
  5. 7 lutego 2021, 8:53 Odpowiedz
  6. 5 lutego 2021, 23:54 Odpowiedz
  7. 2 lutego 2021, 20:44 Odpowiedz
  8. 31 stycznia 2021, 10:16
    18F-FDG brain PET hypometabolism in patients with long COVID Odpowiedz
  9. 29 stycznia 2021, 18:26
    mmune response to SARS-CoV-2 in the nasal mucosa in children and adults Odpowiedz
  10. 26 stycznia 2021, 19:35 Odpowiedz
  11. 25 stycznia 2021, 21:36
    Immunobiology: The Immune System in Health and Disease. 5th edition. Odpowiedz
  12. 24 stycznia 2021, 17:49
    Do an Altered Gut Microbiota and an Associated Leaky Gut Affect COVID-19 Severity? Odpowiedz
  13. 23 stycznia 2021, 18:44
    Allergic Reactions Including Anaphylaxis Odpowiedz
  14. 22 stycznia 2021, 20:11 Odpowiedz
  15. 22 stycznia 2021, 19:52 Odpowiedz
  16. 22 stycznia 2021, 19:51 Odpowiedz
  17. 22 stycznia 2021, 17:09
    Early induction of functional SARS-CoV-2 specific T cells ....... Odpowiedz
  18. 17 stycznia 2021, 19:40 Odpowiedz
  19. 16 stycznia 2021, 15:40 Odpowiedz
  20. 14 stycznia 2021, 16:08
    Positive association between COVID-19 deaths and influenza vaccination rates in elderly people worldwide Odpowiedz
  21. 14 stycznia 2021, 15:46 Odpowiedz
  22. 13 stycznia 2021, 20:24
    Three reasons why COVID-19 can cause silent hypoxia Odpowiedz
  23. 11 stycznia 2021, 17:37 Odpowiedz
  24. 10 stycznia 2021, 11:14
    Influenza Update: Seasonal and H1N1 Vaccines (Inactivating the neuraminidase part prevents further morbidity and mortality, and targeting the M2 protein part of the virus offers the potential for universal influenza vaccine production if the M2 protein's amino acid sequence remains unchanged.10,11 ) Odpowiedz
  25. 9 stycznia 2021, 14:23 Odpowiedz
  26. 8 stycznia 2021, 10:28 Odpowiedz
  27. 6 stycznia 2021, 15:41
    Antithrombotic Therapy in COVID-19 Odpowiedz
  28. 6 stycznia 2021, 13:31 co Pan Doktor sadzi na ten temat? Odpowiedz
  29. 5 stycznia 2021, 21:36
    Autoimmune anti-DNA antibodies predict disease severity in COVID-19 patients Odpowiedz
  30. 5 stycznia 2021, 10:33 Odpowiedz
  31. 4 stycznia 2021, 23:30,38403.html Odpowiedz
  32. 4 stycznia 2021, 22:58
    Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: an in silico approach Odpowiedz
  33. 4 stycznia 2021, 22:41
    Can melatonin reduce the severity of COVID-19 pandemic? Odpowiedz
  34. 4 stycznia 2021, 17:52
    COVID-19: Significance of antibodies Odpowiedz
  35. 4 stycznia 2021, 14:37 Odpowiedz
  36. 4 stycznia 2021, 11:59 Odpowiedz
  37. 3 stycznia 2021, 20:26 Odpowiedz
  38. 3 stycznia 2021, 10:24
    amantadine SARS ..... PD Odpowiedz
  39. 2 stycznia 2021, 16:24
    Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs Odpowiedz
  40. 2 stycznia 2021, 1:21
    Sufficient niacin supply: the missing puzzle piece to COVID-19, and beyond? Odpowiedz
  41. 1 stycznia 2021, 21:52
  42. 1 stycznia 2021, 15:47
    SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome Odpowiedz
  43. 1 stycznia 2021, 15:31 Odpowiedz
  44. 31 grudnia 2020, 23:48 Odpowiedz
  45. 29 grudnia 2020, 17:41 Odpowiedz
  46. 29 grudnia 2020, 17:38 Odpowiedz
  47. 29 grudnia 2020, 15:19
    Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Odpowiedz
  48. 29 grudnia 2020, 10:04 Odpowiedz
  49. 29 grudnia 2020, 9:59
    Why is COVID-19 less severe in children? Odpowiedz
  50. 28 grudnia 2020, 23:24 Odpowiedz
  51. 28 grudnia 2020, 19:34 Odpowiedz
  52. 27 grudnia 2020, 18:19 Odpowiedz
  53. 26 grudnia 2020, 19:31 Odpowiedz
  54. 25 grudnia 2020, 19:23 Odpowiedz
  55. 24 grudnia 2020, 23:07 Odpowiedz
  56. 24 grudnia 2020, 14:20 Odpowiedz
  57. 24 grudnia 2020, 12:35 Odpowiedz
  58. 24 grudnia 2020, 10:31
    GRYPA 1970 Odpowiedz
  59. 23 grudnia 2020, 16:31
    SARS Odpowiedz
  60. 22 grudnia 2020, 16:15
    SARS Odpowiedz
  61. 21 grudnia 2020, 20:03 Odpowiedz
  62. 19 grudnia 2020, 23:03
    drug in covid 19 Odpowiedz
  63. 19 grudnia 2020, 20:20
    SARS-CoV-2 Spike mutations Odpowiedz
  64. 17 grudnia 2020, 23:56
    Amanta Odpowiedz
  65. 17 grudnia 2020, 23:27
    SARS-CoV2 Odpowiedz
  66. 17 grudnia 2020, 18:08
    Exposure to Renin-Angiotensin System Odpowiedz
  67. 17 grudnia 2020, 17:09
    UK GOV Odpowiedz
  68. 17 grudnia 2020, 17:03
    UK Odpowiedz
  69. 17 grudnia 2020, 14:55 Odpowiedz
  70. 17 grudnia 2020, 12:05
    Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion Odpowiedz
  71. 17 grudnia 2020, 12:02
    Danske forskeres inhalationsbehandling af Covid-19 består test i dyr Odpowiedz
  72. 16 grudnia 2020, 15:41
    Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome Odpowiedz
  73. 16 grudnia 2020, 10:46
    (ACE2) Odpowiedz
  74. 15 grudnia 2020, 14:28
    do przeczytania publikacja,drugi-typ-enzymu-konwertujacego-angiotensyne-mozliwa-rola-w-nadcisnieniu-tetniczym-i-chorobach Odpowiedz
  75. 15 grudnia 2020, 0:52
    SPARK Drug Repurposing Conference Tel Aviv University Oct 2020 Odpowiedz
  76. 14 grudnia 2020, 13:59
    Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Odpowiedz
  77. 12 grudnia 2020, 12:05
    MELATONINA Odpowiedz
  78. 7 grudnia 2020, 19:27 Odpowiedz
  79. 6 grudnia 2020, 17:06 Odpowiedz
  80. 6 grudnia 2020, 14:39 Odpowiedz
  81. 6 grudnia 2020, 13:33
    do posłuchania Odpowiedz
  82. 4 grudnia 2020, 23:22 Odpowiedz
  83. 4 grudnia 2020, 22:27 Odpowiedz
  84. 4 grudnia 2020, 22:18 Odpowiedz
  85. 3 grudnia 2020, 20:25
    Синтез производных адамантана. Odpowiedz
  86. 1 grudnia 2020, 21:42
    Мидантан Odpowiedz
  87. 30 listopada 2020, 15:58
    Very great рost. I just stumbled upon your weblog and wantеԁ to mention that I have really lⲟved Ƅгowsing your weblog posts. After all I will be subscribing on your rѕs feed and I ɑm hoping you write agaіn very soon! Odpowiedz
  88. 29 listopada 2020, 19:30
    SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology Odpowiedz
  89. 29 listopada 2020, 19:28
    TEST TEST COVID Odpowiedz
  90. 28 listopada 2020, 13:34
    Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Odpowiedz
  91. 27 listopada 2020, 11:46
    I do agree with all of the ideas you have presented in your post. Theyre really convincing and will definitely work. Still, the posts are very short for beginners. Could you please extend them a bit from next time? Thanks for the post. Odpowiedz
  92. 26 listopada 2020, 21:27
    Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs Odpowiedz
  93. 25 listopada 2020, 21:03
    SARS 2004 Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs Odpowiedz
    • 25 listopada 2020, 21:03 Odpowiedz
  94. 25 listopada 2020, 19:05
    NMDA Inhibitors Odpowiedz
  95. 24 listopada 2020, 15:39
    book Odpowiedz
  96. 23 listopada 2020, 16:45
    bromhexine for the prevention and management of SARS-CoV-2 infection Odpowiedz
  97. 23 listopada 2020, 16:26
    Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 Odpowiedz
  98. 22 listopada 2020, 16:09
    po PL,profilaktyka-i-leczenie-grypy-w-sezonie-zachorowan?page=2 Odpowiedz
  99. 22 listopada 2020, 11:27
    Sars covv 2 Odpowiedz
  100. 21 listopada 2020, 9:59
    Coronavirus (COVID-19) ..... Odpowiedz
  101. 20 listopada 2020, 20:08
    SARS-CoV-2 , COVID , Natural deletions .... Odpowiedz
  102. 18 listopada 2020, 20:17
    Amantadine: an antiviral and antiparkinsonian agent Odpowiedz
  103. 18 listopada 2020, 18:36
    STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters Central and peripheral nervous system complications of COVID-19: A prospective tertiary center cohort with 3-month follow-up Odpowiedz
  104. 18 listopada 2020, 17:37
    The genetic structure of SARS‐CoV‐2 does not rule out a laboratory origin A continuously self-sterilizing form of copper capable of 99% SARS-CoV-2 deactivation in 30 seconds. Odpowiedz
  105. 17 listopada 2020, 21:45
    Influenza and COVID-19 Odpowiedz
  106. 17 listopada 2020, 19:33
    Superiority of cilostazol among antiplatelet FDA‐approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach Discovery of rhodomyrtone as a broad-spectrum antiviral inhibitor with anti-SARS-CoV-2 activity Intra-host evolution during SARS-CoV-2 persistent infection Interferon-b trial shows positive results Role of air temperature and humidity in the transmission of SARS-CoV-2 in the United States Odpowiedz
  107. 17 listopada 2020, 16:48
    JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality Odpowiedz
  108. 16 listopada 2020, 16:34
    Rheumatoid arthritis drug shows promise against COVID-19, study finds Odpowiedz
  109. 16 listopada 2020, 16:33
    Amantadine effective in COVID-19 ? Odpowiedz
  110. 16 listopada 2020, 16:26
    Researchers identify promising new compounds to potentially treat novel coronaviruses Odpowiedz
  111. 16 listopada 2020, 15:25
    Baricitinib treatment linked to reduced mortality in COVID-19 patients Odpowiedz
  112. 15 listopada 2020, 21:57
    Szanowny Panie Doktorze. Czy można uzyskać informacje jakie dawki Pan stosował u pacjentow. Dziękuję. Tomasz Odpowiedz
  113. 15 listopada 2020, 19:56
    drug Odpowiedz
  114. 15 listopada 2020, 19:44
    Potential Effects of Coronaviruses on the Cardiovascular System Odpowiedz
  115. 15 listopada 2020, 18:02
    Antiviral effects of nisin, lysozyme, lactoferrin and their mixtures against bovine viral diarrhoea virus Odpowiedz
  116. 15 listopada 2020, 17:15
    A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2 Odpowiedz
  117. 15 listopada 2020, 12:13
    Amantadine disrupts lysosomal gene expression; potential therapy for COVID19” Odpowiedz
  118. 13 listopada 2020, 11:12
    Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Odpowiedz
  119. 13 listopada 2020, 11:00
    Volunteers who received the Pfizer coronavirus vaccine have said it left them with side effects that felt similar to a “severe hangover,” Odpowiedz
  120. 13 listopada 2020, 10:15
    Functional and druggability analysis of the SARS-CoV-2 proteome Odpowiedz
  121. 13 listopada 2020, 10:08
    Structure and drug binding of the SARS-CoV-2 Odpowiedz
  122. 13 listopada 2020, 10:06
    Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication Odpowiedz
  123. 12 listopada 2020, 14:14
    SARS-CoV-2 vaccines in development Odpowiedz
  124. 12 listopada 2020, 11:00
    było na wykopie Odpowiedz
  125. 11 listopada 2020, 13:35
    Fajnie się czyta, z racji że Covid mnie zamknął w mieszkaniu będę wpadać częściej Odpowiedz
  126. 9 listopada 2020, 5:43
    Gwiazdor to człowiek, który latami pracuje jak opętany, by zyskać popularność, a potem zakłada polaryzacyjne okulary, żeby go nie rozpoznano... :-). Odpowiedz
  127. 8 listopada 2020, 20:13 Odpowiedz
  128. 7 listopada 2020, 15:30
    to było w kwietniu Odpowiedz
  129. 6 listopada 2020, 21:51
    Uprzejmie proszę o uaktualnienie strony, myślę że te informacje warto rozpowszechniać też za granicą. Odpowiedz
    • 6 listopada 2020, 22:05
      Pracujemy nad tym, powinna się pojawić jutro. Odpowiedz
  130. 6 listopada 2020, 20:51
    Amantadine for influenza A Odpowiedz
  131. 2 listopada 2020, 15:42
    Bardzo dziękuję Panu Doktorowi za podpowiedz jak leczyć chorych w domu. Moja uwaga- jak najszybciej , przy najmniejszych pierwszych objawach podawać !!! Wirus uszkadza również osrodek oddechowy- w pewnym momencie mąz miał 6 oddechow na minutę, saturacja 80 - po ząłożeniu CPAP, bez tlenu- saturacja wróciła na 95%, i tak kilka razy- bez maski 80-87 max, z maską 95 i wyżej bez tlenu - Jutro dam ef....... , może prawidłowo ruszy tor oddychowy Ma nadkazenie bakteryjne/ niestety po Levoxie z V. zaczynają się drżenia grubofalowe mięsni ale jestesmy juz na 2 x 1 tabl więc uwaga na interakcje !!! Pozdrawiam wszystkich Ukłony dla Pana Doktora. Odpowiedz
  132. 31 października 2020, 19:45
    Panie doktorze, prosze sie nie poddawac. Wiemy, ze cenzuruja wszystko co nie jest zgodne z wytycznymi. Odpowiedz
  133. 31 października 2020, 1:12
    Kto Pana nastraszył? Odpowiedz
    • 15 grudnia 2020, 17:40
      Widac, ze lobby farmaceutyczne ma swoje macki wszedzie. Odpowiedz

Dodaj komentarz